US5919903A - Low affinity human IL-12 beta2 receptor - Google Patents

Abstract

A recombinant human IL-12 receptor complex produced on the surface of a non-human mammalian cell and free from other human proteins, the complex comprising the beta1 receptor protein complexed with a beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity. A recombinant human IL-12 beta2 receptor protein produced on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein or the recombinant human IL-12 receptor complex, which cell proliferates in the presence of human IL-12. A non-human mammalian cell having the human IL-12 beta2 receptor protein or the complex expressed on its surface and which proliferates in response to human IL-12 is useful for determining whether a given compound inhibits biological activity of human IL-12 or is an IL-12 agonist.

Description

This is a division of application Ser. No. 08/685,118, filed Jul. 23 1996, pending, which claims the benefit of U.S. Provisional application Ser. Nos. 60/001,701 and 60/018,674, filed Aug. 1, 1995 and May 30, 1996, respectively, the United States.

FIELD OF INVENTION

This invention relates generally to human Interleukin-12 receptors.

BACKGROUND OF THE INVENTION

Interleukin-12 (IL-12), formerly known as cytotoxic lymphocyte maturation factor or natural killer cell stimulatory factor, is a 75-KDa heterodimeric cytokine composed of disulfide-bonded 40-KDa (p40) and 35-KDa (p35) subunits that has multiple biological activities including stimulation of the proliferation of activated T and NK cells (Gately, M. K., et al., 1991, J. Immunol., 147:874) (Kobayashi, M., et al., 1989, J. Exp. Med., 170:827), enhancement of the lytic activity of NK/LAK cells (Kobayashi, M., et al., 1989, J. Exp. Med., 170:827; Stern, A. S., et al., 1990, Proc. Natl. Acad. Sci. USA, 87:6808), enhancement of cytolytic T-cell responses (Gately, M. K., et al., 1992, Cell. Immunology, 143:127), induction of interferon gamma by resting and activated T- and NK-cells (Kobayashi, M. et al., 1989, J. Exp. Med., 170:827; Chan, S. H., et al., 1991, J. Exp. Med., 173:869), and promotion of T_h 1-type helper cell responses (Manetti, R., et al., 1993, J. Exp. Med., 177:1199; Hsieh, C.-S., et al., 1993, Science 260:547).

The biological activity of IL-12 is mediated by the binding of the IL-12 molecules to cell surface, or plasma membrane, receptors on activated T- and NK cells; however, the contributions of the individual subunits, p35 and p40, to receptor binding and signal transduction remain unknown. Studies with labeled IL-12 have shown that this binding occurs in a specific and saturable manner. IL-12 delivers a signal to target cells through a receptor that was initially characterized on phytohaemagglutinin (PHA)-activated CD4+ and CD8+ T-cells and on IL-2 activated CD56+ NK-cells (Chizzonite, R., et al., 1992, J. Immunol., 148:3117; Desai, B., et al., 1992, J. Immunol., 148:3125).

A survey of over 20 human cell lines belonging to the T-, B-, NK- and myelomonocytic lineages only identified a single CD4+, IL-2 dependent human T-cell line (Kit 225/K6) that constitutively expresses the IL-12 receptor and responds to IL-12 (Desai, B., et al., 1992, J. Immunol., 148:3125; Desai, B., et al., 1993, J. Immunol. 150:207A). Freshly prepared PHA-activated peripheral blood mononuclear cells (PBMC) and the Kit 225/K6 cell line thus represent two convenient cell sources to study the biochemistry of the functional IL-12 receptor; there may be others.

Equilibrium binding experiments with ¹²⁵ I-labeled IL-12 identified three sites with binding affinities for human IL-12 of 5-20 pM, 50-200 pM, and 2-6 nM on IL-12 responsive T-cells (Chizzonite, R., et al., 1994, Cytokine 6(5):A82a).

A cDNA encoding a low affinity IL-12 receptor was previously cloned (Chua, A., et al, 1994, J. Immunology 153:128; U.S. patent application Ser. No. 08/248,532, filed May 31, 1994 (incorporated herein by reference)). Based on a previously suggested nomenclature (Stahl and Yancopoulos, 1993, Cell 74:587), we now call the initially isolated human IL-12 receptor chain the beta1 chain. However, because (i) this isolated human IL-12 beta1 receptor chain binds human IL-12 with low affinity, and (ii) IL-12 responsive T-cells have a high affinity binding site for human IL-12, another human IL-12 receptor chain must exist.

SUMMARY OF THE INVENTION

We have found that the IL-12 receptor comprises a complex of the beta1 receptor protein with a beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity. We have isolated the DNA encoding the human IL-12 beta2 receptor protein and produced a recombinant human IL-12 beta2 receptor protein on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, we produced a recombinant human IL-12 receptor complex on the surface of a non-human mammalian cell, free from other human proteins, having a high binding affinity for human IL-12. In addition, we produced a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein, which cell proliferates in the presence of human IL-12. In addition, we produced a non-human mammalian cell having expressed on its surface the recombinant human IL-12 receptor complex, which cell proliferates in the presence of human IL-12.

In accordance with this invention, a non-human mammalian cell having the human IL-12 beta2 receptor protein or the complex expressed on its surface and which proliferates in response to human IL-12 is useful for determining IL-12 bioactivity. For example, such cells are useful for determining whether a given compound inhibits biological activity of human IL-12 or is an IL-12 agonist.

In addition, through the ability to express the human IL-12 beta2 receptor protein on a non-human mammalian cell surface, we can also express fragments of the human IL-12 beta2 receptor protein, and can determine whether these fragments, when complexed with the beta1 subunit, or an active fragment thereof, have the same properties and high binding affinity for IL-12 as the intact complex.

We can use the isolated DNA encoding the human IL-12 beta2 receptor protein to make a purified, recombinant protein which is soluble, and which binds to IL-12 with the same affinity as human IL-12 beta2 receptor protein. We can also use the isolated DNA encoding the human IL-12 beta2 receptor protein to make a purified, recombinant protein which is soluble, and which binds to IL-12 with the same affinity as the recombinant human IL-12 receptor complex of the beta1 receptor protein with the beta2 receptor protein See, for example, Charnow, S. M. et al., Trends in Biotechnology, Vol. 14, 52-60 (1996)!.

Such purified, recombinant proteins, which bind to human IL-12, are useful for preventing or treating pathological conditions caused by excess or inappropriate activity of cells possessing IL-12 receptors, by inhibiting binding of IL-12 to such cells. Pathological conditions caused by excess activity of cells possessing IL-12 receptors include autoimmune dysfunctions, such as without limitation rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

A purified, recombinant protein which is soluble, and which binds to IL-12 with the same affinity as human IL-12 beta2 receptor protein is the fusion of a soluble fragment of human IL-12 beta2 receptor protein and a human Ig heavy chain (such as IgG, IgM or IgE, preferably IgG) having all domains except the first domain of the constant region. This recombinant protein is encoded by a chimeric polynucleotide which has 2 DNA subsequences fused in frame. The first DNA subsequence, at the 5' end of the chimeric polynucleotide, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta2 receptor protein. The second DNA subsequence, located at the 3' end of the chimeric polynucleotide, is an isolated DNA sequence encoding all domains of a human heavy chain Ig (preferably IgG) except the first domain of the constant region. The desired recombinant protein can be generated by transfection of the chimeric polynucleotide into a non-human mammalian cell, such as a chinese hamster ovary (CHO) cell. The expressed recombinant protein can be purified, for example, by protein G affinity chromatography.

A purified, recombinant protein which is soluble, and which binds to IL-12 with the same affinity as the recombinant human IL-12 receptor complex of the beta1 receptor with the beta2 receptor is encoded by two chimeric polynucleotides which each have two DNA subsequences fused in frame. The first DNA subsequence of the first chimeric polynucleotide, located at the 5' end, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta2 receptor protein. The second DNA subsequence of the first chimeric polynucleotide, located at the 3' end, is an isolated DNA sequence encoding all domains of a human Ig heavy chain (for example, IgG, IgM, IgE, preferably IgG) except the first domain of the constant region. The first DNA subsequence of the second chimeric polynucleotide, located at the 5' end, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta1 receptor protein. The second DNA subsequence of the second chimeric polynucleotide, located at the 3' end, is an isolated DNA sequence encoding all domains of a human Ig heavy chain (for example, IgG, IgM, IgE, preferably IgG) except the first domain of the constant region. The desired recombinant protein may be generated by cotransfection of the two chimeric polynucleotides into a non human mammalian cell, such as a CHO cell. The expressed protein can be purified, for example, by any method that enables differentiation of homodimeric proteins from heterodimeric proteins, such as, for example, column chromatography.

In addition, monoclonal or polyclonal antibodies directed against the human IL-12 beta2 receptor protein, or fragments thereof, or the complex, may also be produced by known methods See, for example, Current Protocols in Immunology, edt. by Coligan, J. E. et al., J. Wiley & Sons (1992)! and used to prevent or treat pathological conditions caused by excess activity of cells possessing IL-12 receptors by inhibiting binding of IL-12 to such cells.

DETAILED DESCRIPTION OF THE INVENTION

We have found that the human IL-12 receptor comprises a complex of the beta1 receptor protein with the beta2 receptor protein, which complex is capable of binding to human IL-12 with high affinity. We have isolated the DNA encoding the human IL-12 beta2 receptor protein and produced a recombinant human IL-12 beta2 receptor protein on the surface of a non-human mammalian cell, free from other human proteins, in its active form. In addition, we produced a recombinant human IL-12 receptor complex on the surface of a non-human mammalian cell, free from other human proteins, having a high binding affinity for human IL-12. In addition, we produced a non-human mammalian cell having expressed on its surface the recombinant human IL-12 beta2 receptor protein, which cell proliferates in the presence of human IL-12. In addition, we produced a non-human mammalian cell having expressed on its surface the recombinant human IL-12 receptor complex, which cell proliferates in the presence of human IL-12.

The following terms shall have the following definitions set forth below:

Human IL-12 beta2 receptor protein refers to (1) the protein of SEQ ID NO:2, or (2) any protein or polypeptide having an amino acid sequence which is substantially homologous to the amino acid sequence SEQ ID NO:2 and which has the following properties:

1) The protein or polypeptide has low binding affinity for human IL-12, and

2) The protein or polypeptide, when complexed with human beta1 receptor protein forms a complex having high binding affinity for human IL-12.

Human IL-12 beta1 receptor protein refers to (1) the protein of SEQ ID NO:4, or (2) any protein or polypeptide having an amino acid sequence which is substantially homologous to the amino acid sequence SEQ ID NO:4 and which has the following properties:

1) The protein or polypeptide binds to has low binding affinity for human IL-12, and

2) The protein or polypeptide, when complexed with human beta2 receptor protein forms a complex having high binding affinity for human IL-12.

As used herein, the terms human IL-12 beta2 receptor protein and human IL-12 beta1 receptor protein includes proteins modified deliberately, as for example, by site directed mutagenesis or accidentally through mutations.

Substantially homologous, which can refer both to nucleic acid and amino acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from the reference sequence by one or more substitutions, deletions, or additions, the net effect of which do not result in an adverse functional dissimilarity between the reference and subject sequences. For purposes of the present invention, sequences having greater than 95% homology, equivalent biological properties, and equivalent expression characteristics are considered substantially homologous. For purposes of determining homology, truncation of the mature sequence should be disregarded. Sequences having lesser degrees of homology, comparable bioactivity, and equivalent expression characterisitics are considered substantial equivalents. Generally, homologous DNA sequences can be identified b y cross-hybridization under high stringency hybridization conditions.

Fragment of the human IL-12 beta2 receptor protein means any protein or polypeptide having the amino acid sequence of a portion or fragment of human IL-12 beta2 receptor protein, and which (a) has low binding affinity for human IL-12, and (2) when complexed with a human IL-12 beta1 receptor protein, forms a complex having high binding affinity for human IL-12.

Fragment of the human IL-12 beta1 receptor protein means any protein or polypeptide having the amino acid sequence of a portion or fragment of human IL-12 beta1 receptor protein, and which when complexed with a human IL-12 beta2 receptor protein, forms a complex having high binding affinity for human IL-12.

Expression vector is a genetic element capable of replication under its own control, such as a plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment. It comprises a transciptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters and enhancers, (2) a structural or coding sequence which is transcribed into mRNA and translated into protein, and (3) appropriate transcription initiation and termination sequences.

Clone is a group of identical DNA molecules derived from one original length of DNA sequence and produced by a bacterium or virus using genetic engineering techniques, often involving plasmids.

Soluble fragment refers to a fragment of a human IL-12 receptor protein having an amino acid sequence corresponding to all or part of the extracellular region of the protein and which retains the IL-12 binding activity of the intact IL-12 receptor protein. For example, a soluble fragment of a human IL-12 beta2 receptor protein is a fragment of a human IL-12 beta2 receptor protein having an amino acid sequence corresponding to all or part of the extracellular region of a human IL-12 beta2 receptor protein.

Expression of Human IL-12 Receptor Protein Having High Binding Affinity to Human IL-12

The cDNA of cells where the human IL-12 receptor is known to be found is incorporated by conventional methods into a bacterial host to establish a cDNA library. PHA-activated PBMC and cells from the Kit 225/K6 cell line are examples of cell sources for the cDNA. RNA from the cells is extracted, characterized, and transcribed into single stranded cDNA by conventional methods. The single stranded cDNA is converted into double stranded cDNA by conventional methods. The double stranded cDNA is incorporated by conventional techniques into an expression vector, such as pEF-BOS. The plasmid DNA from the expression vector is then incorporated into a bacterial host by conventional methods to form a library of recombinants.

The cDNA library is screened by conventional expression screening methods, as described by Hara and Mijayima, 1992, EMBO, 11:1875, for cDNA's which when expressed with cDNA's for the human IL-12 beta1 receptor protein, give rise to a high affinity human IL-12 receptor. A small number of clones from the library are grown in pools. DNA is extracted by conventional methods from the pools of clones. The DNA extracted from a pool of clones is then transfected by conventional methods, along with a small amount of DNA from a plasmid containing the cDNA encoding the human IL-12 beta1 receptor protein, into non-human host cells. The non-human host cells are preferably mammalian, such as a COS cell. Labeled recombinant human IL-12 is then added to the non-human host cells previously transfected as described above and the binding signal of the pool is determined. This process is repeated for each pool. The pools showing a positive binding signal for IL-12 may then be subsequently broken down into smaller pools and reassayed in the above manner until a single clone is selected which shows a positive binding signal.

The plasmid DNA from the selected clone is sequenced on both strands using conventional methods, such as an ABI automated DNA sequencer in conjunction with a thermostable DNA polymerase and dye-labeled dideoxynucleotides as terminators. Amino acid sequence alignments may be run as described by M. O. Dayhoff et al., Methods Enzymology 91:524 (1983) with the mutation data matrix, a break penalty of 6 and 100 random runs.

The DNA from the selected clone is then co-transfected by conventional methods with DNA from a plasmid containing the cDNA encoding the human IL-12 beta1 receptor protein into a non-human host cell, preferably a non-human mammalian cell such as a COS cell or a Ba/F3 cell.

Alternatively, by conventional recombinant methods, a plasmid may be engineered which contains transcription units (promoter, cDNA, and polyA regions) for both human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein. Plasmid DNA is transfected by conventional methods into a non-human host cell, preferably a non-human mammalian cell such as a COS cell or a Ba/F3 cell.

In accordance with the invention, a complex comprising human IL-12 beta2 receptor protein, or a fragment thereof, complexed with human IL-12 beta1 receptor protein, or a fragment thereof, may be expressed on the cell surface of the non-human host cell. When expressed on the cell surface of the non-human host cell, the complex has a high binding affinity for human IL-12, whereas the human IL-12 beta1 receptor protein and the human IL-12 beta2 receptor protein alone each have a low binding affinity for human IL-12.

In accordance with this invention, we can also express on the surface of a non-human host cell human IL-12 beta2 receptor protein.

In accordance with this invention, not only can the human IL-12 beta2 receptor protein be obtained, we can also obtain fragments of human IL-12 beta2 receptor protein which (1) has low binding affinity for human IL-12 and (2) which when complexed with a human IL-12 beta1 receptor protein forms a complex having high binding affinity. The fragments of human IL-12 beta2 receptor protein may be obtained by conventional means, such as (i) proteolytic degradation of the human IL-12 beta2 receptor protein, (ii) chemical synthesis by methods routine in the art, or (iii) standard recombinant methods.

For purposes of the present invention, a human IL-12 receptor protein which has a high binding affinity for human IL-12 is a protein which binds to human IL-12 with a binding affinity of from about 5 to about 100 pM. For purposes of the present invention, a human IL-12 receptor protein which has a low binding affinity for human IL-12 is a protein which binds to human IL-12 with a binding affinity of from about 1 to about 10 nM. The binding affinity of a protein for human IL-12 can be determined by conventional means, such as desribed in R. Chizzonite et al., 1992, J. Immunol., 148:3117 and as set forth in Example 5.

Fragments of human IL-12 beta2 receptor protein can also be measured for binding affinity for human IL-12 by conventional means, such as desribed in R. Chizzonite et al., 1992, J. Immunol., 148:3117 and as set forth in Example 5. The fragments of human IL-12 beta2 receptor protein may be measured for binding affinity for human IL-12 either alone or complexed with human IL-12 beta1 receptor protein, or a fragment of human IL-12 beta1 receptor protein which when complexed with a human IL-12 beta2 receptor protein forms a complex having high binding affinity.

In accordance with this invention, we can isolate DNA which encodes a complex capable of binding to human IL-12 with high affinity, the complex comprising human IL-12 beta2 receptor protein, or a fragment thereof, and human IL-12 beta1 receptor protein, or a fragment thereof.

In accordance with this invention, we can also isolate DNA which encodes human IL-12 beta2 receptor protein, or a fragment thereof, which fragment (1) has low binding affinity for human IL-12 and (2) when complexed with human IL-12 beta1 receptor protein, forms a complex having high binding affinity for human IL-12.

An isolated DNA sequence refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, that is, free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the sequence and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such sequences are preferably provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA containing the relevant sequences could also be used as a source of coding sequences. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

In accordance with this invention, we can also make, by known methods, a purified, recombinant protein which is the fusion of a soluble fragment of human IL-12 beta2 receptor protein and a human Ig heavy chain (preferably IgG) containing all domains except the first domain of the constant region. This recombinant protein, which is homodimeric, is encoded by a chimeric polynucleotide which has 2 DNA subsequences fused in frame. The first DNA subsequence, at the 5' end of the chimeric polynucleotide, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta2 receptor protein. The second DNA subsequence, located at the 3' end of the chimeric polynucleotide, is an isolated DNA sequence encoding all domains of a human Ig heavy chain (preferably IgG) except the first domain of the constant region.

In addition, we can make, by known methods, a purified, recombinant protein comprising two different polypeptide chains (a heterodimeric protein). The two different polypeptide chains are each encoded by a different chimeric polynucleotide which has two DNA subsequences fused in frame. The first DNA subsequence of the first chimeric polynucleotide, located at its 5' end, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta2 receptor protein. The second DNA subsequence of the first chimeric polynucleotide, located at its 3' end, is an isolated DNA sequence encoding all domains of a human Ig heavy chain (preferably IgG) except the first domain of the constant region. The first DNA subsequence of the second chimeric polynucleotide, located at its 5' end, is an isolated DNA sequence encoding a soluble fragment of human IL-12 beta1 receptor protein. The second DNA subsequence of the second chimeric polynucleotide, located at its 3' end, is an isolated DNA sequence encoding all domains of a human Ig heavy chain (preferably IgG) except the first domain of the constant region.

The starting materials for the purified, recombinant proteins of the invention may be obtained by methods known in the art. In particular, on the basis of the DNA sequence coding for human IL-12 beta2 receptor protein described in SEQ ID NO:1 and of the already known DNA sequences for certain receptors, those partial DNA sequences which code for a soluble fragment of human IL-12 beta2 receptor protein can be determined and engineered from the DNA sequence coding for human IL-12 beta2 receptor protein described in SEQ ID NO:1 using known methods, see Sambrook et al., "Molecular Cloning", 2nd ed., Cold Spring Harbor Laboratory Press (1989). Similarly, on the basis of the DNA sequence coding for human IL-12 beta1 receptor protein described in SEQ ID NO:3 and of the already known DNA sequences for certain receptors, those partial DNA sequences which code for a soluble fragment of human IL-12 beta1 receptor protein can be determined and engineered from the DNA sequence coding for human IL-12 beta1 receptor protein described in SEQ ID NO:3 using known methods, see Sambrook et al., "Molecular Cloning", 2nd ed., Cold Spring Harbor Laboratory Press (1989). Sources for isolated DNA sequences coding for constant domains of human immunoglobulins are known in the art and disclosed, for example, by Ellison et al., Nucl. Acid Res. 10, 4071-4079 (1982) for IgG₁ or Huck et al., Nucl. Acid Res. 14, 1779-1789 (1986) for IgG₃.

The isolated DNA sequence encoding the soluble fragment of human IL-12 beta2 receptor protein may be fused in frame, by known methods Sambrook et al., "Molecular Cloning", 2nd ed., Cold Spring Harbor Laboratory Press (1989)!, to the isolated DNA sequence encoding all domains of a human Ig heavy chain (preferably IgG) except the first domain of the constant region. The resulting chimeric polynucleotide has located at its 5' end the isolated DNA sequence encoding the soluble fragment of human IL-12 beta2 receptor protein and at its 3' end the isolated DNA sequence encoding all domains of the human Ig heavy chain except the first domain of the constant region.

Similarly, the isolated DNA sequence encoding the soluble fragment of human IL-12 beta1 receptor protein may be fused in frame, by known methods Sambrook et al., "Molecular Cloning", 2nd ed., Cold Spring Harbor Laboratory Press (1989)!, to the isolated DNA sequence encoding all domains of a human Ig heavy chain (preferably IgG) except the first domain of the constant region. The resulting chimeric polynucleotide has located at its 5' end the isolated DNA sequence encoding the soluble fragment of human IL-12 beta1 receptor protein and at its 3' end the isolated DNA sequence encoding all domains of a human Ig heavy chain except the first domain of the constant region.

The chimeric polynucleotides can then be integrated using known methods Sambrook et al., "Molecular Cloning", 2nd ed., Cold Spring Harbor Laboratory Press (1989)! into suitable expression vectors for expression in a non-human mammalian cell, such as a CHO cell. In order to make the homodimeric protein of the invention, the chimeric polynucleotide having located at its 5' end the isolated DNA sequence encoding the soluble fragment of human IL-12 beta2 receptor protein is integrated into a suitable expression vector. In order to make the heterodimeric protein of the invention, the chimeric polynucleotide having located at its 5' end the isolated DNA sequence encoding the soluble fragment of human IL-12 beta2 receptor protein and the chimeric polynucleotide having located at its 5' end the isolated DNA sequence encoding the soluble fragment of human IL-12 beta1 receptor protein are integrated into a single suitable expression vector, or two separate suitable expression vectors.

Preferably, the chimeric polynucleotide(s) is/are co-transfected together with a selectable marker, for example neomycin, hygromycin, dihydrofolate reductase (dhfr) or hypoxanthin guanine phosphoribosyl transferase (hgpt) using methods which are known in the art. The DNA sequence stably incorporated in the chromosome can subsequently be amplified. A suitable selection marker for this is, for example, dhfr. Mammalian cells, for example, CHO cells, which contain no intact dhfr gene, are thereby incubated with increasing amounts of methotrexate after transfection has been performed. In this manner, cell lines which contain a higher number of the desired DNA sequence than the unamplified cells can be obtained.

The baculovirus expression system can also be used for the expression of recombinant proteins in insect cells. Postranslational modifications performed by insect cells are very similar to those occurring in mammalian cells. For the production of a recombinant baculovirus which expresses the desired protein a transfer vector is used. A transfer vector is a plasmid which contains the chimeric polynucleotide(s) under the control of a strong promoter, for example, that of the polyhedron gene, surrounded on both sides by viral sequences. The transfer vector is then transfected into the insect cells together with the DNA sequence of the wild type baculovirus. The recombinant viruses which result in the cells by homologous recombination can then be identified and isolated according to known methods. When using the baculovirus expression system, DNA sequences encoding the immunoglobulin part have to be in the form of cDNA.

The expressed recombinant protein may be purified, for example, by known methods. For example, protein G affinity chromatography may be used to purify the homodimeric protein of the invention. Column chromatography, or any other method that enables differentiation between homodimeric proteins and heterodimeric proteins, may be used to purify the heterodimeric protein of the invention.

Such purified, recombinant proteins are useful for preventing or treating pathological conditions caused by excess or inappropriate activity of cells possessing IL-12 receptors by inhibiting binding of IL-12 to such cells.

"Purified", as used to define the purity of a recombinant protein encoded by the combined DNA sequences described above, or protein compositions thereof, means that the protein or protein composition is substantially free of other proteins of natural or endogenous origin and contains less than about 1% by mass of protein contaminants residual of production processes. Such compositions, however, can contain other proteins added as stabilizers, carders, excipients or co-therapeutics. A protein is purified if it is detectable, for example, as a single protein band in a polyacrylamide gel by silver staining.

Purified recombinant proteins as described above (as well as antibodies to the human IL-12 beta2 receptor proteins and fragments thereof, and antibodies to the complex of this invention) can be administered in clinical treatment of autoimmune dysfunctions, such as without limitation rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

The purified recombinant proteins described above (as well as antibodies to the human IL-12 beta2 receptor proteins and fragments thereof, and antibodies to the complex of this invention) can be used in combination with other cytokine antagonists such as antibodies to the IL-2 receptor, soluble TNF (tumor necrosis factor) receptor, the IL-1 antagonist, and the like to treat or prevent the above disorders or conditions.

The dose ranges for the administration of the purified, recombinant proteins described above (as well as antibodies to the human IL-12 beta2 receptor proteins and fragments thereof, and antibodies to the complex of this invention) may be determined by those of ordinary skill in the art without undue experimentation. In general, appropriate dosages are those which are large enough to produce the desired effect, for example, blocking the binding of endogenous IL-12 to its natural receptor. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of disease in the patient, counter indications, if any, immune tolerance and other such variables, to be adjusted by the individual physician. The purified, recombinant proteins described above (as well as antibodies to the human IL-12 beta2 receptor proteins and fragments thereof, and antibodies to the complex of this invention) can be administered parenterally by injection or by gradual perfusion over time. They can be administered intravenously, intraperitoneally, intramuscularly, or subcutaneously.

Preparations for parenteral adminstration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcohol/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replinishers, electrolyte replinishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, anti-micorbials, anti-oxidants, chelating agents, inert gases and the like. See, generally, Remington's Pharmaceutical Science, 16th Ed., Mack Eds., 1980.

Assays for Determining Whether a Given Compound Blocks IL-12 Activity

An aspect of the invention is the use of either the human IL-12 beta2 receptor protein or the complex of this invention as a screening agent for pharmaceuticals. In accordance with this invention, we can determine whether a given compound blocks human IL-12 activity or acts as an agonist of IL-12.

A biological activity of human IL-12 is the stimulation of the proliferation of activated T- and NK-cells. Proliferation of activated T-cells causes alloantigen-induced immune responses, such as allograft rejection (such as skin, kidney, and heart transplants) and graft-versus-host reaction in patients who have received bone marrow transplants. This biological activity of human IL-12 is mediated by the binding of the human IL-12 molecules to cell surface receptors on the activated T-cells.

A compound that blocks human IL-12 activity would, therefore, inhibit the proliferation of activated T-cells and would be useful to treat or prevent alloantigen induced immune responses.

In order to determine if a compound blocks human IL-12 activity, first, a plurality of cells having expressed on their surface either the human IL-12 beta2 receptor protein or a fragment thereof, or the complex of the invention, which cells proliferate in the presence of human IL-12, is provided. The human IL-12 beta2 receptor protein or a fragment thereof binds to human IL-12 with low binding affinity, but when complexed with human beta1 receptor protein forms a complex having high binding affinity for human IL-12. The complex of the invention binds to human IL-12 with high binding affinity and comprises a complex of (1) human IL-12 beta2 receptor protein, or a fragment thereof which when complexed with a human IL-12 beta1 receptor protein forms a complex having high binding affinity to human IL-12, and (2) human IL-12 beta1 receptor protein, or a fragment thereof which when complexed with a human IL-12 beta2 receptor protein forms a complex having high binding affinity to human IL-12. Second, the cells are contacted with human IL-12 and the given compound. Third, it is determined whether the presence of the given compound inhibits proliferation of the cells.

In order to determine if a compound is an agonist of human IL-12, first, a plurality of cells having expressed on their surface either the human IL-12 beta2 receptor protein or a fragment thereof, or the complex of the invention, and which cells proliferate in the presence of human IL-12, is provided. The human IL-12 beta2 receptor protein or a fragment thereof binds to human IL-12 with low binding affinity, but when complexed with human beta1 receptor protein forms a complex having high binding affinity for human IL-12. The complex of the invention binds to human IL-12 with high binding affinity and comprises a complex of (1) human IL-12 beta2 receptor protein, or a fragment thereof which when complexed with a human IL-12 beta1 receptor protein forms a complex having high binding affinity to human IL-12, and (2) human IL-12 beta1 receptor protein, or a fragment thereof which when complexed with a human IL-12 beta2 receptor protein forms a complex having high binding affinity to human IL-12. Second, the cells are contacted with human IL-12 or the given compound. Third, it is determined whether the presence of the given compound stimulates proliferation of the cells.

Examples of cells capable of expressing on their surface the complex, which cells proliferate in the presence of human IL-12 include, without limitation, PHA-activated PBMC, Kit 225/K6 cells, and Ba/F3 cells transfected with cDNA for both human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein. Examples of cells capable of expressing on their surface the human IL-12 beta2 receptor protein, or a fragment thereof, which cells proliferate in the presence of human IL-12 include, without limitation, Ba/F3 cells transfected with cDNA for human IL-12 beta2 receptor protein.

In order to determine whether the presence of the given compound inhibits proliferation of the cells, the following procedure may be carried out. The human IL-12 responsive cells, having expressed on their surface the human IL-12 beta2 receptor protein, or a fragment thereof, or the human IL-12 receptor complex of the invention, are plated into wells of a microtiter plate. Human IL-12 is then added to some wells of the microtiter plate (standard wells) and allowed to react with the cells. The compound to be tested is added either before or simultaneously with human IL-12 to different wells of the microtiter plate (sample wells) and allowed to react with the cells. Any solvent used must be non-toxic to the cell. The proliferation of the cells is then measured by known methods, for example, labeling the cells after contact with human IL-12 and the compound (such as by incorporation of tritiated thymidine into the replicating DNA), measuring the accumulation of cellular metabolites (such as lactic acid), and the like. The proliferation of the cells of the standard wells is compared to proliferation of the cells of the sample wells. If the cells of the sample wells proliferate significantly less than the cells of the standard wells, the compound blocks IL-12 activity.

In order to determine whether the presence of the given compound simulates proliferation of the cells, the following procedure may be carried out. The human IL-12 responsive cells having expressed on their surface the human IL-12 beta2 receptor protein, or a fragment thereof, or the human IL-12 receptor complex of the invention are plated into wells of a microtiter plate. Human IL-12 is then added to some wells of the microtiter plate (standard wells) and allowed to react with the cells. The compound to be tested is added to different wells of the microtiter plate (sample wells) and allowed to react with the cells. Any solvent used must be non-toxic to the cell. The proliferation of the cells is then measured by known methods, for example, labeling the cells after contact with the compound (such as by incorporation of tritiated thymidine into the replicating DNA), measuring the accumulation of cellular metabolites (such as lactic acid), and the like. The proliferation of the cells of the standard wells is compared to proliferation of the cells of the sample wells. If the cells of the sample wells proliferate significantly more than cells that were not exposed to human IL-12, the compound is an agonist of human IL-12.

The following examples are offered by way of illustration, not by limitation.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS MATERIALS

Proteins, Plasmids and Strains

Recombinant human IL-12 (U. Gubler et al., 1991, Proc. Natl. Acad. Sci. USA., 88:4143) was obtained as described therein.

Recombinant human IL-2 (H. W. Lahm et al., 1985, J. Chromatog, 326:357) was obtained as described therein

The plasmid pEF-BOS was obtained from Dr. Nagata at the Osaka Bioscience Institute in Japan. The plasmid is based on a pUC 119 backbone and contains the elongation factor 1 alpha promoter to drive expression of genes inserted at the BstXI site (S. Mizushima and S. Nagata, Nucl. Acids Res., 1990, 18:5322).

The human IL-12 receptor beta1 cDNA in the plasmid pEF-BOS was obtained as described in A. Chua et al., 1994, J. Immunology 153:128 and in U.S. patent application Ser. No. 08/248,532, filed May 31, 1994, now U.S. Pat. No. 5,536,657.

Electrocompetent E.coli DH-10B (S. Grant et al., 1990, Proc. Natl. Acad. Sci USA 87:4645) was obtained from Bethesda Research Laboratory (Bethesda, Md.).

METHODS

Labeling of Human IL-12 With ¹²⁵ I

Recombinant human IL-12 was labeled with ¹²⁵ I as follows. Iodogen was dissolved in chloroform. 0.05 mg aliquots of lodogen were dried in 12×150 mm borosilicate glass tubes. For radiolabeling, 1.0 mCi Na ¹²⁵ I! was added to the Iodogen-coated borosilicate glass tube, which also contained 0.05 ml of Tris-iodination buffer (25 mM Tris-HCL pH 7.5, 0.4 M NaCl and 1 mM EDTA) to form a ¹²⁵ I solution. The ¹²⁵ I solution was activated by incubating for 6 minutes at room temperature. The activated ¹²⁵ I solution was transferred to a tube containing 0.05 to 0.1 ml recombinant human IL-12 (31.5 μg) in Tris-iodination buffer. The resulting mixture of the activated ¹²⁵ I solution and the recombinant human IL-12 was incubated for 6 minutes at room temperature. At the end of the incubation, 0.05 ml of lodogen stop buffer (10 mg/ml tyrosine, 10% glycerol in Dulbecco's phosphate buffered saline (PBS), pH 7.40) was added and reacted for 3 minutes. The resulting mixture was then diluted with 1.0 ml Tris-iodination buffer containing 0.25% bovine serum albumin (BSA), and applied to a Bio-Gel P10DG desalting column for chromatography. The column was eluted with Tris-iodination buffer containing 0.25% BSA. 1 ml fractions containing the eluted peak amounts of labeled recombinant human IL-12 were combined. The combined fractions were diluted to 1×10⁸ cpm/ml with 1% BSA in Tris-iodination buffer. Incorporation of ¹²⁵ I into recombinant human IL-12 was monitered by precipitation with trichloroacetic acid (TCA). The TCA precipitable radioactivity (10% TCA final concentration) was typically in excess of 95% of the total radioactivity. The radiospecific activity of the labeled recombinant human IL-12 was typically 1000 to 2000 cpm/fmole.

EXAMPLE 1 Preparation of Human PHA-activated Lymphoblasts

Human peripheral blood mononuclear cells (PBMC) were isolated from blood collected from healthy donors as described in Gately et al., J. Natl. Cancer Inst. 69, 1245 (1982). The blood was collected into heparinized syringes, diluted with an equal volume of Hank's balanced salt solution and layered over lymphocyte separation medium (LSM® obtained from Organon Teknika Corporation, Durham, N.C.) in tubes. The tubes were spun at 2000 rpm for 20 minutes at room temperature. PBMC at the interface of the aqueous blood solution and the lymphocyte separation medium were collected. Collected PBMC were pelleted at 1500 rpm for 10 minutes through a 15 ml cushion of 20% sucrose in Hank's balanced salt solution. Pelleted PBMC were resuspended in tissue culture medium (1:1 mixture of RPMI 1640 and Dulbecco's modified Eagle's medium, supplemented with 0.1 mM nonessential amino acids, 60 μg/ml arginine HCl, 10 mM Hepes buffer, 2 μM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 0.05 mM 2-mercaptoethanol, and 1 μg/ml dextrose) (TCM) plus 5% human serum and washed twice in TCM.

The PBMC were then activated to form lymphoblasts. In particular, 0.5-1×10⁶ cells/ml in TCM plus 5% human serum plus 0.1% (v/v) PHA-P (Difco, Detroit, Mich.) were cultured for 3 days at 37° C. in a 5% CO₂ atmosphere.

After three days, cell cultures were split 1:1 by volume in TCM plus 5% human serum and 50 U/ml recombinant human IL-2 to yield >95% T-cells. These cells were utilized for preparation of a cDNA library.

EXAMPLE 2 Extraction and Characterization of RNA

PBMC isolated as in Example 1, activated with PHA for 2-3 days, were harvested and total RNA was extracted using Guanidine Isothiocyanate/Phenol as described by P. Chomczynski and N. Sacchi, Anal. Biochem., 162:156, 1987. PolyA⁺ RNA was isolated from the total RNA by one batch adsorption to oligo dT latex beads as described (K. Kuribayashi et al., Nucl. Acids Res. Symposium Series 19:61, 1988). The mass yield of this purification was about 4% of polyA+ RNA.

EXAMPLE 3 cDNA Library

From the above polyA⁺ RNA, a cDNA library was established in the mammalian expression vector pEF-BOS as follows.

3 μg of polyA⁺ RNA were reverse transcribed into single stranded cDNAs using RNaseH minus reverse transcriptase in the presence of α-³² P-dCTP. The resulting single stranded cDNAs were converted into blunt ended double stranded cDNAs as described by U. Gubler and A. Chua, Essential Molecular Biology Volume II, T. A. Brown, editor, pp. 39-56, IRL Press 1991. BstXI linkers (A. Aruffo and B. Seed, Proc. Natl. Acad. Sci (USA) 84, 8573, 1987) were ligated to the resulting double stranded cDNAs.

cDNA molecules having a size of greater than 800 base pairs (bp) were selected by size exclusion chromatography as follows. A Sephacryl SF 500 column (0.8×29 cm) was packed by gravity in 10 mM Tris-HCl pH 7.8--1 mM EDTA--100 mM NaAcetate. The radioactive cDNA with added BstXI linkers was applied to the column and 0.5 ml fractions were collected. The size distribution of radioactive cDNA was determined by performing electrophoresis on a small aliquot of each fraction on a 1% agarose gel, drying the gel, and visualizing the size by exposure of the gel to X-ray film. cDNA molecules larger than 800 bp were size selected in this fashion.

The selected cDNA molecules were pooled and concentrated by ethanol precipitation. The pooled and concentrated selected cDNA molecules were subsequently ligated to the plasmid pEF-BOS as follows. The plasmid had been restricted with BstXI and purified over two consecutive 1% agarose gels. 300 ng of the restricted and purified plasmid DNA were ligated to 30 ng of size selected cDNA in 60 μl of ligation buffer (50 mM Tris-HCl pH 7.8--10 mM MgCl₂ --10 mM DTT--1 mM rATP--25 mg/ml BSA) at 15° C. overnight.

The following day, the plasmid ligated with the size selected cDNA was extracted with phenol. 6 mg of mussel glycogen were added to the resulting extract, and the nucleic acids were precipitated by ethanol. The resulting precipitate was dissolved in water and the nucleic acids again were precipitated by ethanol, followed by a wash with 80% ethanol. A pellet was formed from the precipitated and washed nucleic acids. The pellet was dissolved in 6 μl of water. 1 μl aliquots of the dissolved pellet were subsequently electroporated into E.Coli strain DH-10B. Upon electroporated of 5 parallel aliquots, a library of about 10 million recombinants was generated.

EXAMPLE 4 Expression Screening for cDNAs Encoding High Affinity IL-12 Receptors

The library was screened according to the general expression screening method described by Hara and Miyajima, 1992, EMBO, 11:1875.

Pools of about 100 E.coli clones from the above library were grown and the plasmid DNA was extracted from the pools by conventional methods. 2×10⁵ COS cells were plated per 35 mm culture well. COS cells were transfected with a transfection cocktail using the standard DEAE dextran technique described in "Molecular Cloning, a Laboratory Manual", 2nd Ed., J. Sambrook et al., Cold Spring Harbor Laboratory Press, 1989 ("Molecular Cloning"). The transfection cocktail contained (1) 1 μg of plasmid DNA extracted from the E.coli clone pools derived from the above library, and (2) 0.1 μg of pEF-BOS plasmid DNA containing the human IL-12 receptor beta1 cDNA.

3 days after transfection, the wells of COS cells were incubated with 10 pM labeled human recombinant IL-12 (specific activity=1000-2000 cpm/fmole) for 90 minutes at room temperature. The labeled human recombinant IL-12 was removed, and the COS cell monolayer was washed for one hour three times with binding buffer (RPMI 1640, 5% fetal bovine serum (FBS), 25 mM HEPES pH 7) to further select for COS cells expressing high affinity IL-12 receptors only (the binding of the IL-12 ligand to the low affinity sites was further reduced because the low affinity sites have a higher dissociation rate). Subsequently, the cell monolayers were lysed and counted in a gamma counter. After screening 440 pools (representing about 44,000 clones), one pool consistently showed a positive binding signal (300 cpm over 100 cpm background). From this pool, a single clone was subsequently isolated by sib-selection. This single clone (B5-10) contained a cDNA insert of about 3 kb that was completely sequenced.

The cDNA insert of clone B5-10 was incomplete with regard to the protein coding region because it did not contain an in-frame stop codon. The cDNA library of Example 3 was rescreened by conventional DNA hybridization techniques with the cDNA insert from clone B5-10, as described in Molecular Cloning and by Grunstein and Hogness, 1975, Proc. Nat. Acad. Sci. USA., 72:3961. Additional clones were thus isolated and then partially sequenced. The nucleotide sequence of one clone (No. 3) was found to (i) overlap with the 3' end of the nucleotide sequence of clone B5-10, (ii) extend beyond the nucleotide sequence of clone B5-10, and (iii) contain an in-frame stop codon.

This composite DNA sequence is shown in SEQ ID NO:1. The deduced amino acid sequence for the encoded receptor protein is shown in SEQ ID NO:2. Based on the previously suggested nomenclature of Stahl and Yancopolous, 1993, Cell 74:587, we call this newly isolated human IL-12 receptor chain the beta2 chain.

EXAMPLE 5 Binding Assays

COS cells (4-5×10⁷) were transfected by electroporation using a BioRad Gene Pulser (250 μF, 250 volts) with either (1) 25 μg of the B5-10 plasmid DNA expressing recombinant human IL-12 beta2 receptor protein, (2) 25 μg of the pEF-BOS plasmid DNA expressing recombinant human IL-12 beta1 receptor protein, or (3) a mixture of 12.5 μg of the B5-10 plasmid DNA expressing recombinant human IL-12 beta2 receptor protein and 12.5 μg of the pEF-BOS plasmid DNA expressing recombinant human IL-12 beta1 receptor protein. The electroporated cells were plated in a 600 cm² culture plate, harvested after 72 hours by scraping, washed and resuspended in binding buffer.

The cells were assayed to determine affinities of the expressed IL-12 receptors for human IL-12. In particular, equilibrium binding of labeled recombinant human IL-12 to the cells was performed and analyzed as described by R. Chizzonite, et al., 1992, J. Immunol., 148:3117. Electroporated cells (8×10⁴) were incubated with increasing concentrations of ¹²⁵ I-labeled recombinant human IL-12 at room temperature for 2 hours. Incubations were carried out in duplicate or triplicate.

Cell bound radioactivity was separated from free labeled ¹²⁵ I-IL-12 by centrifugation of the mixture of electroporated cells and ¹²⁵ I-labeled recombinant human IL-12 through 0.1 ml of an oil mixture (1:2 mixture of Thomas Silicone Fluid 6428-R15 {A. H. Thomas} and Silicone Oil AR 200 {Gallard-Schlessinger}) at 4° C. for 90 seconds at 10,000×g to form a cell pellet in a tube. The cell pellet was excised from the tip of the tube in which it was formed, and cell bound radioactivity was determined in a gamma counter.

Receptor binding data were analyzed and the affinities were calculated according to Scatchard using the method described by McPherson, J., 1985, Pharmacol. Methods, 14:213.

EXAMPLE 6 Production of IL-12 Responsive Cell Line

Wild-type Ba/F3 cells, an IL-3-dependent mouse pro-B cell (Palacios, R. et al., 1985, Cell 41:727) and Ba/F3 cells expressing human IL-12 beta1 receptor protein (Chua, A., et al., 1994, J. Imunology 153:128) were cotransfected with (1) 80 μg of pEF-BOS plasmid DNA expressing recombinant human IL-12 beta2 receptor protein and (2) 8 μg of a plasmid expressing a hygromycin resistance gene (Giordano, T. J., et al., 1990, Gene 88:285) by electroporation using a BioRad Gene Pulser (960 μF, 400 volts).

All cells were resuspended at a density of 2×10⁵ viable cells/ml in a growth medium of RPMI 1640, 10% FBS, glutamine (2 mM), penicillin G (100 U/ml), streptomycin (100 μg/ml), and 10% conditioned medium from the WEHI-3 cell line (ATCC No. TIB 68, American Type Culture Collection, Rockville, Md.). The WEHI-3 cell line is a source of IL-3. The resuspended cells were then incubated at 37° C. under 5% CO₂ for 120 hours.

Cells were selected by their ability to grow in (1) the above growth medium in the presence of 1 mg/ml hygromycin or (2) an IL-12 containing growth medium of RPMI 1640, 10% FBS, glutamine (2 mM), penicillin G (100 U/ml), streptomycin (100 μg/ml), and various concentrations (10, 50 or 250 ng/ml) of human IL-12.

Ba/F3 cells expressing human IL-12 beta1 receptor protein transfected with pEF-BOS plasmid DNA expressing recombinant human IL-12 beta2 receptor protein grew in the IL-12 containing growth medium, demonstrating that coexpression of human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein conferred human IL-12 responsiveness to the Ba/F3 cells.

Additionally, Ba/F3 cells expressing human IL-12 beta2 receptor protein grow in the IL-12 containing growth medium, demonstrating that expression of human IL-12 beta2 receptor protein conferred human IL-12 responsiveness to the Ba/F3 cells.

Effect of Human IL-12 on Transfected Ba/F3 Cell Lines

Ba/F3 cells (1) expressing human IL-12 beta1 receptor protein, (2) expressing human IL-12 beta2 receptor protein, or (3) coexpressing human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin G, 100 μg/ml streptomycin, and 2 mM L-glutamine at 2×10⁴ cells/well in Costar 3596 flat-bottom microplates for 24 hours. Various dilutions of human IL-12, as shown in FIG. 6, were then added to the microplates and the cells were incubated for 42 hours at 37° C. in a humidified atmosphere of 5% CO₂ in air. 50 μl of ³ H-thymidine, 10 μCi/ml in culture medium, was then added to each well. The cultures were further incubated for 6 hours at 37° C. Subsequently, the culture contents were harvested onto glass fiber filters by means of a cell harvester. ³ H-thymidine incorporation was measured by use of a liquid scintillation counter. All samples were assayed in quadruplicate.

Results Sequence Analysis of IL-12 Receptor cDNA Clones and Encoded IL-12 Receptor Protein

The IL-12 beta2 receptor protein, composed of 862 amino acids and a calculated molecular weight of 97231, had the following features: N-terminal signal peptide, extracellular domain, transmembrane domain and cytoplasmic tail. The classical hydrophobic N-terminal signal peptide is predicted to be 23 amino acids in length. Signal peptide cleavage occurs mostly after the amino acids Ala, Ser, Gly, Cys, Thr, Gln (von Heijne, G., 1986, Nucl. Acids Research, 14:4683). For the IL-12 receptor, the cleavage could thus take place after Ala23 in the sequence shown in SEQ ID NO:2, leaving a mature protein of 839 amino acids based on cleavage at Ala23. The extracellular domain of the receptor is predicted to encompass the region from the C-terminus of the signal peptide to amino acid No. 622 in the sequence shown in SEQ ID NO:2. Hydrophobicity analysis shows the area from amino acid No. 623 to 646 to be hydrophobic, as would be expected for a transmembrane anchor region. Charged transfer stop residues can be found at the N- as well as the C-terminus of this predicted transmembrane area. The extracellular domain of the receptor is thus 599 amino acids long and contains 9 predicted N-linked glycosylation sites. The cytoplasmic portion is 215 amino acids long (amino acid residue nos. 647 to 862).

Further analysis of the amino acid sequence shown in SEQ ID NO:2 shows the human IL-12 beta2 receptor protein is a member of the cytokine receptor superfamily, by virtue of the sequence motifs Cys132 - - - Cys143TW! and W305SKWS!. Comparing the sequence shown in SEQ ID NO:2 to all the members of the superfamily by running the ALIGN program shows that the human IL-12 beta2 receptor protein has the highest homology to human gp130. The cytoplasmic region of the IL-12 receptor beta2 chain contains the box 1 and 2 motifs found in other cytokine receptor superfamily members, as well as three tyrosine residues. Phosphorylation of tyrosines is commonly associated with cytokine receptor signalling; the presence of these tyrosine residues underscores the importance of the IL-12 receptor beta2 chain in the formation of a functional IL-12 receptor. The IL-12 receptor beta1 chain does not contain any tyrosine residues in its cytoplasmic tail.

Binding Assays

We have found that human IL-12 binds to recombinant IL-12 receptor beta1 or beta2 alone with an apparent affinity of about 2-5 nM. The binding data was described by a single site receptor model, corresponding to the low affinity component of the functional IL-12 receptor found on PHA-activated PBMC (R. Chizzonite et al., 1992, J. Immunol., 148:3117; B. Desai et al., 1992, J. Immunol., 148:3125).

In contrast to these results, both high and low affinity IL-12 binding sites were generated upon cotransfection of COS cells with IL-12 receptor beta1 and beta2 plasmids. In this case, the binding data were described by a two receptor site model, with affinities of 50 pM and 5 nM.

Effect of Human IL-12 on Transfected Ba/F3 Cell Lines

We conducted a proliferation assay for the effect of human IL-12 on Ba/F3 cells (1) expressing human IL-12 beta1 receptor protein, (2) expressing human IL-12 beta2 receptor protein, and (3) coexpressing human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein

We have found that cells that are transfected with cDNAs for both human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein respond to stimulation by human IL-12 by proliferating in a dose-dependent manner.

Additionally, we have found that cells that are transfected with cDNAs for human IL-12 beta2 receptor protein respond to stimulation by human IL-12 by proliferating in a dose-dependent manner.

Conclusion

The isolated cDNA (clone No. B5-10, SEQ ID No:1) coding for a type I transmembrane protein represents a second component of the IL-12 receptor (IL-12R beta2) found on normal human T-cells. The beta1 and beta2 chains each alone bind IL-12 only with low affinity (Kd=2-5 nM). Upon coexpression of beta1 and beta2, two affinity sites are observed, with Kd values of 50 pM and 5 nM.

Ba/F3 cells expressing human IL-12 beta2 receptor protein or coexpressing human IL-12 beta1 receptor protein and human IL-12 beta2 receptor protein are responsive to human IL-12.

The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, it being recognized that various modifications are possible within the scope of the invention.

__________________________________________________________________________
#             SEQUENCE LISTING
- (1) GENERAL INFORMATION:
-    (iii) NUMBER OF SEQUENCES: 4
- (2) INFORMATION FOR SEQ ID NO:1:
-      (i) SEQUENCE CHARACTERISTICS:
#pairs    (A) LENGTH: 4040 base
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: double
          (D) TOPOLOGY: linear
-     (ii) MOLECULE TYPE: cDNA
-    (iii) HYPOTHETICAL: NO
-     (iv) ANTI-SENSE: NO
-     (ix) FEATURE:
          (A) NAME/KEY: CDS
          (B) LOCATION: 641..3226
-     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- TGCAGAGAAC AGAGAAAGGA CATCTGCGAG GAAAGTTCCC TGATGGCTGT CA - #ACAAAGTG
  60
- CCACGTCTCT ATGGCTGTGT ACGCTGAGCA CACGATTTTA TCGCGCCTAT CA - #TATCTTGG
 120
- TGCATAAACG CACCTCACCT CGGTCAACCC TTGCTCCGTC TTATGAGACA GG - #CTTTATTA
 180
- TCCGCATTTT ATATGAGGGG AATCTGACGG TGGAGAGAGA ATTATCTTGC TC - #AAGGCGAC
 240
- ACAGCAGAGC CCACAGGTGG CAGAATCCCA CCCGAGCCCG CTTCGACCCG CG - #GGGTGGAA
 300
- ACCACGGGCG CCCGCCCGGC TGCGCTTCCA GAGCTGAACT GAGAAGCGAG TC - #CTCTCCGC
 360
- CCTGCGGCCA CCGCCCAGCC CCGACCCCCG CCCCGGCCCG ATCCTCACTC GC - #CGCCAGCT
 420
- CCCCGCGCCC ACCCCGGAGT TGGTGGCGCA GAGGCGGGAG GCGGAGGCGG GA - #GGGCGGGC
 480
- GCTGGCACCG GGAACGCCCG AGCGCCGGCA GAGAGCGCGG AGAGCGCGAC AC - #GTGCGGCC
 540
- CAGAGCACCG GGGCCACCCG GTCCCCGCAG GCCCGGGACC GCGCCCGCTG GC - #AGGCGACA
 600
- CGTGGAAGAA TACGGAGTTC TATACCAGAG TTGATTGTTG ATG GCA CA - #T ACT TTT
 655
#        Met Ala His Thr Phe
#       5  1
- AGA GGA TGC TCA TTG GCA TTT ATG TTT ATA AT - #C ACG TGG CTG TTG ATT
 703
Arg Gly Cys Ser Leu Ala Phe Met Phe Ile Il - #e Thr Trp Leu Leu Ile
#                 20
- AAA GCA AAA ATA GAT GCG TGC AAG AGA GGC GA - #T GTG ACT GTG AAG CCT
 751
Lys Ala Lys Ile Asp Ala Cys Lys Arg Gly As - #p Val Thr Val Lys Pro
#             35
- TCC CAT GTA ATT TTA CTT GGA TCC ACT GTC AA - #T ATT ACA TGC TCT TTG
 799
Ser His Val Ile Leu Leu Gly Ser Thr Val As - #n Ile Thr Cys Ser Leu
#         50
- AAG CCC AGA CAA GGC TGC TTT CAC TAT TCC AG - #A CGT AAC AAG TTA ATC
 847
Lys Pro Arg Gln Gly Cys Phe His Tyr Ser Ar - #g Arg Asn Lys Leu Ile
#     65
- CTG TAC AAG TTT GAC AGA AGA ATC AAT TTT CA - #C CAT GGC CAC TCC CTC
 895
Leu Tyr Lys Phe Asp Arg Arg Ile Asn Phe Hi - #s His Gly His Ser Leu
# 85
- AAT TCT CAA GTC ACA GGT CTT CCC CTT GGT AC - #A ACC TTG TTT GTC TGC
 943
Asn Ser Gln Val Thr Gly Leu Pro Leu Gly Th - #r Thr Leu Phe Val Cys
#                100
- AAA CTG GCC TGT ATC AAT AGT GAT GAA ATT CA - #A ATA TGT GGA GCA GAG
 991
Lys Leu Ala Cys Ile Asn Ser Asp Glu Ile Gl - #n Ile Cys Gly Ala Glu
#           115
- ATC TTC GTT GGT GTT GCT CCA GAA CAG CCT CA - #A AAT TTA TCC TGC ATA
1039
Ile Phe Val Gly Val Ala Pro Glu Gln Pro Gl - #n Asn Leu Ser Cys Ile
#       130
- CAG AAG GGA GAA CAG GGG ACT GTG GCC TGC AC - #C TGG GAA AGA GGA CGA
1087
Gln Lys Gly Glu Gln Gly Thr Val Ala Cys Th - #r Trp Glu Arg Gly Arg
#   145
- GAC ACC CAC TTA TAC ACT GAG TAT ACT CTA CA - #G CTA AGT GGA CCA AAA
1135
Asp Thr His Leu Tyr Thr Glu Tyr Thr Leu Gl - #n Leu Ser Gly Pro Lys
150                 1 - #55                 1 - #60                 1 -
#65
- AAT TTA ACC TGG CAG AAG CAA TGT AAA GAC AT - #T TAT TGT GAC TAT TTG
1183
Asn Leu Thr Trp Gln Lys Gln Cys Lys Asp Il - #e Tyr Cys Asp Tyr Leu
#               180
- GAC TTT GGA ATC AAC CTC ACC CCT GAA TCA CC - #T GAA TCC AAT TTC ACA
1231
Asp Phe Gly Ile Asn Leu Thr Pro Glu Ser Pr - #o Glu Ser Asn Phe Thr
#           195
- GCC AAG GTT ACT GCT GTC AAT AGT CTT GGA AG - #C TCC TCT TCA CTT CCA
1279
Ala Lys Val Thr Ala Val Asn Ser Leu Gly Se - #r Ser Ser Ser Leu Pro
#       210
- TCC ACA TTC ACA TTC TTG GAC ATA GTG AGG CC - #T CTT CCT CCG TGG GAC
1327
Ser Thr Phe Thr Phe Leu Asp Ile Val Arg Pr - #o Leu Pro Pro Trp Asp
#   225
- ATT AGA ATC AAA TTT CAA AAG GCT TCC GTG AG - #C AGA TGT ACC CTT TAT
1375
Ile Arg Ile Lys Phe Gln Lys Ala Ser Val Se - #r Arg Cys Thr Leu Tyr
230                 2 - #35                 2 - #40                 2 -
#45
- TGG AGA GAT GAG GGA CTG GTA CTG CTT AAT CG - #A CTC AGA TAT CGG CCC
1423
Trp Arg Asp Glu Gly Leu Val Leu Leu Asn Ar - #g Leu Arg Tyr Arg Pro
#               260
- AGT AAC AGC AGG CTC TGG AAT ATG GTT AAT GT - #T ACA AAG GCC AAA GGA
1471
Ser Asn Ser Arg Leu Trp Asn Met Val Asn Va - #l Thr Lys Ala Lys Gly
#           275
- AGA CAT GAT TTG CTG GAT CTG AAA CCA TTT AC - #A GAA TAT GAA TTT CAG
1519
Arg His Asp Leu Leu Asp Leu Lys Pro Phe Th - #r Glu Tyr Glu Phe Gln
#       290
- ATT TCC TCT AAG CTA CAT CTT TAT AAG GGA AG - #T TGG AGT GAT TGG AGT
1567
Ile Ser Ser Lys Leu His Leu Tyr Lys Gly Se - #r Trp Ser Asp Trp Ser
#   305
- GAA TCA TTG AGA GCA CAA ACA CCA GAA GAA GA - #G CCT ACT GGG ATG TTA
1615
Glu Ser Leu Arg Ala Gln Thr Pro Glu Glu Gl - #u Pro Thr Gly Met Leu
310                 3 - #15                 3 - #20                 3 -
#25
- GAT GTC TGG TAC ATG AAA CGG CAC ATT GAC TA - #C AGT AGA CAA CAG ATT
1663
Asp Val Trp Tyr Met Lys Arg His Ile Asp Ty - #r Ser Arg Gln Gln Ile
#               340
- TCT CTT TTC TGG AAG AAT CTG AGT GTC TCA GA - #G GCA AGA GGA AAA ATT
1711
Ser Leu Phe Trp Lys Asn Leu Ser Val Ser Gl - #u Ala Arg Gly Lys Ile
#           355
- CTC CAC TAT CAG GTG ACC TTG CAG GAG CTG AC - #A GGA GGG AAA GCC ATG
1759
Leu His Tyr Gln Val Thr Leu Gln Glu Leu Th - #r Gly Gly Lys Ala Met
#       370
- ACA CAG AAC ATC ACA GGA CAC ACC TCC TGG AC - #C ACA GTC ATT CCT AGA
1807
Thr Gln Asn Ile Thr Gly His Thr Ser Trp Th - #r Thr Val Ile Pro Arg
#   385
- ACC GGA AAT TGG GCT GTG GCT GTG TCT GCA GC - #A AAT TCA AAA GGC AGT
1855
Thr Gly Asn Trp Ala Val Ala Val Ser Ala Al - #a Asn Ser Lys Gly Ser
390                 3 - #95                 4 - #00                 4 -
#05
- TCT CTG CCC ACT CGT ATT AAC ATA ATG AAC CT - #G TGT GAG GCA GGG TTG
1903
Ser Leu Pro Thr Arg Ile Asn Ile Met Asn Le - #u Cys Glu Ala Gly Leu
#               420
- CTG GCT CCT CGC CAG GTC TCT GCA AAC TCA GA - #G GGC ATG GAC AAC ATT
1951
Leu Ala Pro Arg Gln Val Ser Ala Asn Ser Gl - #u Gly Met Asp Asn Ile
#           435
- CTG GTG ACT TGG CAG CCT CCC AGG AAA GAT CC - #C TCT GCT GTT CAG GAG
1999
Leu Val Thr Trp Gln Pro Pro Arg Lys Asp Pr - #o Ser Ala Val Gln Glu
#       450
- TAC GTG GTG GAA TGG AGA GAG CTC CAT CCA GG - #G GGT GAC ACA CAG GTC
2047
Tyr Val Val Glu Trp Arg Glu Leu His Pro Gl - #y Gly Asp Thr Gln Val
#   465
- CCT CTA AAC TGG CTA CGG AGT CGA CCC TAC AA - #T GTG TCT GCT CTG ATT
2095
Pro Leu Asn Trp Leu Arg Ser Arg Pro Tyr As - #n Val Ser Ala Leu Ile
470                 4 - #75                 4 - #80                 4 -
#85
- TCA GAG AAC ATA AAA TCC TAC ATC TGT TAT GA - #A ATC CGT GTG TAT GCA
2143
Ser Glu Asn Ile Lys Ser Tyr Ile Cys Tyr Gl - #u Ile Arg Val Tyr Ala
#               500
- CTC TCA GGG GAT CAA GGA GGA TGC AGC TCC AT - #C CTG GGT AAC TCT AAG
2191
Leu Ser Gly Asp Gln Gly Gly Cys Ser Ser Il - #e Leu Gly Asn Ser Lys
#           515
- CAC AAA GCA CCA CTG AGT GGC CCC CAC ATT AA - #T GCC ATC ACA GAG GAA
2239
His Lys Ala Pro Leu Ser Gly Pro His Ile As - #n Ala Ile Thr Glu Glu
#       530
- AAG GGG AGC ATT TTA ATT TCA TGG AAC AGC AT - #T CCA GTC CAG GAG CAA
2287
Lys Gly Ser Ile Leu Ile Ser Trp Asn Ser Il - #e Pro Val Gln Glu Gln
#   545
- ATG GGC TGC CTC CTC CAT TAT AGG ATA TAC TG - #G AAG GAA CGG GAC TCC
2335
Met Gly Cys Leu Leu His Tyr Arg Ile Tyr Tr - #p Lys Glu Arg Asp Ser
550                 5 - #55                 5 - #60                 5 -
#65
- AAC TCC CAG CCT CAG CTC TGT GAA ATT CCC TA - #C AGA GTC TCC CAA AAT
2383
Asn Ser Gln Pro Gln Leu Cys Glu Ile Pro Ty - #r Arg Val Ser Gln Asn
#               580
- TCA CAT CCA ATA AAC AGC CTG CAG CCC CGA GT - #G ACA TAT GTC CTG TGG
2431
Ser His Pro Ile Asn Ser Leu Gln Pro Arg Va - #l Thr Tyr Val Leu Trp
#           595
- ATG ACA GCT CTG ACA GCT GCT GGT GAA AGT TC - #C CAC GGA AAT GAG AGG
2479
Met Thr Ala Leu Thr Ala Ala Gly Glu Ser Se - #r His Gly Asn Glu Arg
#       610
- GAA TTT TGT CTG CAA GGT AAA GCC AAT TGG AT - #G GCG TTT GTG GCA CCA
2527
Glu Phe Cys Leu Gln Gly Lys Ala Asn Trp Me - #t Ala Phe Val Ala Pro
#   625
- AGC ATT TGC ATT GCT ATC ATC ATG GTG GGC AT - #T TTC TCA ACG CAT TAC
2575
Ser Ile Cys Ile Ala Ile Ile Met Val Gly Il - #e Phe Ser Thr His Tyr
630                 6 - #35                 6 - #40                 6 -
#45
- TTC CAG CAA AAG GTG TTT GTT CTC CTA GCA GC - #C CTC AGA CCT CAG TGG
2623
Phe Gln Gln Lys Val Phe Val Leu Leu Ala Al - #a Leu Arg Pro Gln Trp
#               660
- TGT AGC AGA GAA ATT CCA GAT CCA GCA AAT AG - #C ACT TGC GCT AAG AAA
2671
Cys Ser Arg Glu Ile Pro Asp Pro Ala Asn Se - #r Thr Cys Ala Lys Lys
#           675
- TAT CCC ATT GCA GAG GAG AAG ACA CAG CTG CC - #C TTG GAC AGG CTC CTG
2719
Tyr Pro Ile Ala Glu Glu Lys Thr Gln Leu Pr - #o Leu Asp Arg Leu Leu
#       690
- ATA GAC TGG CCC ACG CCT GAA GAT CCT GAA CC - #G CTG GTC ATC AGT GAA
2767
Ile Asp Trp Pro Thr Pro Glu Asp Pro Glu Pr - #o Leu Val Ile Ser Glu
#   705
- GTC CTT CAT CAA GTG ACC CCA GTT TTC AGA CA - #T CCC CCC TGC TCC AAC
2815
Val Leu His Gln Val Thr Pro Val Phe Arg Hi - #s Pro Pro Cys Ser Asn
710                 7 - #15                 7 - #20                 7 -
#25
- TGG CCA CAA AGG GAA AAA GGA ATC CAA GGT CA - #T CAG GCC TCT GAG AAA
2863
Trp Pro Gln Arg Glu Lys Gly Ile Gln Gly Hi - #s Gln Ala Ser Glu Lys
#               740
- GAC ATG ATG CAC AGT GCC TCA AGC CCA CCA CC - #T CCA AGA GCT CTC CAA
2911
Asp Met Met His Ser Ala Ser Ser Pro Pro Pr - #o Pro Arg Ala Leu Gln
#           755
- GCT GAG AGC AGA CAA CTG GTG GAT CTG TAC AA - #G GTG CTG GAG AGC AGG
2959
Ala Glu Ser Arg Gln Leu Val Asp Leu Tyr Ly - #s Val Leu Glu Ser Arg
#       770
- GGC TCC GAC CCA AAG CCA GAA AAC CCA GCC TG - #T CCC TGG ACG GTG CTC
3007
Gly Ser Asp Pro Lys Pro Glu Asn Pro Ala Cy - #s Pro Trp Thr Val Leu
#   785
- CCA GCA GGT GAC CTT CCC ACC CAT GAT GGC TA - #C TTA CCC TCC AAC ATA
3055
Pro Ala Gly Asp Leu Pro Thr His Asp Gly Ty - #r Leu Pro Ser Asn Ile
790                 7 - #95                 8 - #00                 8 -
#05
- GAT GAC CTC CCC TCA CAT GAG GCA CCT CTC GC - #T GAC TCT CTG GAA GAA
3103
Asp Asp Leu Pro Ser His Glu Ala Pro Leu Al - #a Asp Ser Leu Glu Glu
#               820
- CTG GAG CCT CAG CAC ATC TCC CTT TCT GTT TT - #C CCC TCA AGT TCT CTT
3151
Leu Glu Pro Gln His Ile Ser Leu Ser Val Ph - #e Pro Ser Ser Ser Leu
#           835
- CAC CCA CTC ACC TTC TCC TGT GGT GAT AAG CT - #G ACT CTG GAT CAG TTA
3199
His Pro Leu Thr Phe Ser Cys Gly Asp Lys Le - #u Thr Leu Asp Gln Leu
#       850
- AAG ATG AGG TGT GAC TCC CTC ATG CTC TGAGTGGTG - #A GGCTTCAAGC
3246
Lys Met Arg Cys Asp Ser Leu Met Leu
#   860
- CTTAAAGTCA GTGTGCCCTC AACCAGCACA GCCTGCCCCA ATTCCCCCAG CC - #CCTGCTCC
3306
- AGCAGCTGTC ATCTCTGGGT GCCACCATCG GTCTGGCTGC AGCTAGAGGA CA - #GGCAAGCC
3366
- AGCTCTGGGG GAGTCTTAGG AACTGGGAGT TGGTCTTCAC TCAGATGCCT CA - #TCTTGCCT
3426
- TTCCCAGGGC CTTAAAATTA CATCCTTCAC TGTGTGGACC TAGAGACTCC AA - #CTTGAATT
3486
- CCTAGTAACT TTCTTGGTAT GCTGGCCAGA AAGGGAAATG AGGAGGAGAG TA - #GAAACCAC
3546
- AGCTCTTAGT AGTAATGGCA TACAGTCTAG AGGACCATTC ATGCAATGAC TA - #TTTCTAAA
3606
- GCACCTGCTA CACAGCAGGC TGTACACAGC AGATCAGTAC TGTTCAACAG AA - #CTTCCTGA
3666
- GATGATGGAA ATGTTCTACC TCTGCACTCA CTGTCCAGTA CATTAGACAC TA - #GGCACATT
3726
- GGCTGTTAAT CACTTGGAAT GTGTTTAGCT TGACTGAGGA ATTAAATTTT GA - #TTGTAAAT
3786
- TTAAATCGCC ACACATGGCT AGTGGCTACT GTATTGGAGT GCACAGCTCT AG - #ATGGCTCC
3846
- TAGATTATTG AGAGCCTCCA AAACAAATCA ACCTAGTTCT ATAGATGAAG AC - #ATAAAAGA
3906
- CACTGGTAAA CACCAATGTA AAAGGGCCCC CAAGGTGGTC ATGACTGGTC TC - #ATTTGCAG
3966
- AAGTCTAAGA ATGTACCTTT TTCTGGCCGG GCGTGGTAGC TCATGCCTGT AA - #TCCCAGCA
4026
#   4040
- (2) INFORMATION FOR SEQ ID NO:2:
-      (i) SEQUENCE CHARACTERISTICS:
#acids    (A) LENGTH: 862 amino
          (B) TYPE: amino acid
          (D) TOPOLOGY: linear
-     (ii) MOLECULE TYPE: protein
-     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
- Met Ala His Thr Phe Arg Gly Cys Ser Leu Al - #a Phe Met Phe Ile Ile
#                 15
- Thr Trp Leu Leu Ile Lys Ala Lys Ile Asp Al - #a Cys Lys Arg Gly Asp
#             30
- Val Thr Val Lys Pro Ser His Val Ile Leu Le - #u Gly Ser Thr Val Asn
#         45
- Ile Thr Cys Ser Leu Lys Pro Arg Gln Gly Cy - #s Phe His Tyr Ser Arg
#     60
- Arg Asn Lys Leu Ile Leu Tyr Lys Phe Asp Ar - #g Arg Ile Asn Phe His
# 80
- His Gly His Ser Leu Asn Ser Gln Val Thr Gl - #y Leu Pro Leu Gly Thr
#                 95
- Thr Leu Phe Val Cys Lys Leu Ala Cys Ile As - #n Ser Asp Glu Ile Gln
#           110
- Ile Cys Gly Ala Glu Ile Phe Val Gly Val Al - #a Pro Glu Gln Pro Gln
#       125
- Asn Leu Ser Cys Ile Gln Lys Gly Glu Gln Gl - #y Thr Val Ala Cys Thr
#   140
- Trp Glu Arg Gly Arg Asp Thr His Leu Tyr Th - #r Glu Tyr Thr Leu Gln
145                 1 - #50                 1 - #55                 1 -
#60
- Leu Ser Gly Pro Lys Asn Leu Thr Trp Gln Ly - #s Gln Cys Lys Asp Ile
#               175
- Tyr Cys Asp Tyr Leu Asp Phe Gly Ile Asn Le - #u Thr Pro Glu Ser Pro
#           190
- Glu Ser Asn Phe Thr Ala Lys Val Thr Ala Va - #l Asn Ser Leu Gly Ser
#       205
- Ser Ser Ser Leu Pro Ser Thr Phe Thr Phe Le - #u Asp Ile Val Arg Pro
#   220
- Leu Pro Pro Trp Asp Ile Arg Ile Lys Phe Gl - #n Lys Ala Ser Val Ser
225                 2 - #30                 2 - #35                 2 -
#40
- Arg Cys Thr Leu Tyr Trp Arg Asp Glu Gly Le - #u Val Leu Leu Asn Arg
#               255
- Leu Arg Tyr Arg Pro Ser Asn Ser Arg Leu Tr - #p Asn Met Val Asn Val
#           270
- Thr Lys Ala Lys Gly Arg His Asp Leu Leu As - #p Leu Lys Pro Phe Thr
#       285
- Glu Tyr Glu Phe Gln Ile Ser Ser Lys Leu Hi - #s Leu Tyr Lys Gly Ser
#   300
- Trp Ser Asp Trp Ser Glu Ser Leu Arg Ala Gl - #n Thr Pro Glu Glu Glu
305                 3 - #10                 3 - #15                 3 -
#20
- Pro Thr Gly Met Leu Asp Val Trp Tyr Met Ly - #s Arg His Ile Asp Tyr
#               335
- Ser Arg Gln Gln Ile Ser Leu Phe Trp Lys As - #n Leu Ser Val Ser Glu
#           350
- Ala Arg Gly Lys Ile Leu His Tyr Gln Val Th - #r Leu Gln Glu Leu Thr
#       365
- Gly Gly Lys Ala Met Thr Gln Asn Ile Thr Gl - #y His Thr Ser Trp Thr
#   380
- Thr Val Ile Pro Arg Thr Gly Asn Trp Ala Va - #l Ala Val Ser Ala Ala
385                 3 - #90                 3 - #95                 4 -
#00
- Asn Ser Lys Gly Ser Ser Leu Pro Thr Arg Il - #e Asn Ile Met Asn Leu
#               415
- Cys Glu Ala Gly Leu Leu Ala Pro Arg Gln Va - #l Ser Ala Asn Ser Glu
#           430
- Gly Met Asp Asn Ile Leu Val Thr Trp Gln Pr - #o Pro Arg Lys Asp Pro
#       445
- Ser Ala Val Gln Glu Tyr Val Val Glu Trp Ar - #g Glu Leu His Pro Gly
#   460
- Gly Asp Thr Gln Val Pro Leu Asn Trp Leu Ar - #g Ser Arg Pro Tyr Asn
465                 4 - #70                 4 - #75                 4 -
#80
- Val Ser Ala Leu Ile Ser Glu Asn Ile Lys Se - #r Tyr Ile Cys Tyr Glu
#               495
- Ile Arg Val Tyr Ala Leu Ser Gly Asp Gln Gl - #y Gly Cys Ser Ser Ile
#           510
- Leu Gly Asn Ser Lys His Lys Ala Pro Leu Se - #r Gly Pro His Ile Asn
#       525
- Ala Ile Thr Glu Glu Lys Gly Ser Ile Leu Il - #e Ser Trp Asn Ser Ile
#   540
- Pro Val Gln Glu Gln Met Gly Cys Leu Leu Hi - #s Tyr Arg Ile Tyr Trp
545                 5 - #50                 5 - #55                 5 -
#60
- Lys Glu Arg Asp Ser Asn Ser Gln Pro Gln Le - #u Cys Glu Ile Pro Tyr
#               575
- Arg Val Ser Gln Asn Ser His Pro Ile Asn Se - #r Leu Gln Pro Arg Val
#           590
- Thr Tyr Val Leu Trp Met Thr Ala Leu Thr Al - #a Ala Gly Glu Ser Ser
#       605
- His Gly Asn Glu Arg Glu Phe Cys Leu Gln Gl - #y Lys Ala Asn Trp Met
#   620
- Ala Phe Val Ala Pro Ser Ile Cys Ile Ala Il - #e Ile Met Val Gly Ile
625                 6 - #30                 6 - #35                 6 -
#40
- Phe Ser Thr His Tyr Phe Gln Gln Lys Val Ph - #e Val Leu Leu Ala Ala
#               655
- Leu Arg Pro Gln Trp Cys Ser Arg Glu Ile Pr - #o Asp Pro Ala Asn Ser
#           670
- Thr Cys Ala Lys Lys Tyr Pro Ile Ala Glu Gl - #u Lys Thr Gln Leu Pro
#       685
- Leu Asp Arg Leu Leu Ile Asp Trp Pro Thr Pr - #o Glu Asp Pro Glu Pro
#   700
- Leu Val Ile Ser Glu Val Leu His Gln Val Th - #r Pro Val Phe Arg His
705                 7 - #10                 7 - #15                 7 -
#20
- Pro Pro Cys Ser Asn Trp Pro Gln Arg Glu Ly - #s Gly Ile Gln Gly His
#               735
- Gln Ala Ser Glu Lys Asp Met Met His Ser Al - #a Ser Ser Pro Pro Pro
#           750
- Pro Arg Ala Leu Gln Ala Glu Ser Arg Gln Le - #u Val Asp Leu Tyr Lys
#       765
- Val Leu Glu Ser Arg Gly Ser Asp Pro Lys Pr - #o Glu Asn Pro Ala Cys
#   780
- Pro Trp Thr Val Leu Pro Ala Gly Asp Leu Pr - #o Thr His Asp Gly Tyr
785                 7 - #90                 7 - #95                 8 -
#00
- Leu Pro Ser Asn Ile Asp Asp Leu Pro Ser Hi - #s Glu Ala Pro Leu Ala
#               815
- Asp Ser Leu Glu Glu Leu Glu Pro Gln His Il - #e Ser Leu Ser Val Phe
#           830
- Pro Ser Ser Ser Leu His Pro Leu Thr Phe Se - #r Cys Gly Asp Lys Leu
#       845
- Thr Leu Asp Gln Leu Lys Met Arg Cys Asp Se - #r Leu Met Leu
#   860
- (2) INFORMATION FOR SEQ ID NO:3:
-      (i) SEQUENCE CHARACTERISTICS:
#pairs    (A) LENGTH: 2104 base
          (B) TYPE: nucleic acid
          (C) STRANDEDNESS: double
          (D) TOPOLOGY: linear
-     (ii) MOLECULE TYPE: cDNA to mRNA
-    (iii) HYPOTHETICAL: NO
-     (vi) ORIGINAL SOURCE:
          (A) ORGANISM: Homo sapi - #ens
#T-cells  (G) CELL TYPE: human
-    (vii) IMMEDIATE SOURCE:
#day PHA/pEF-BOSBRARY: library 3
          (B) CLONE: human interl - #eukin-12 receptor clone #5
-     (ix) FEATURE:
          (A) NAME/KEY: CDS
          (B) LOCATION: 65..2050
-     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
- GGTGGCTGAA CCTCGCAGGT GGCAGAGAGG CTCCCCTGGG GCTGTGGGGC TC - #TACGTGGA
  60
- TCCG ATG GAG CCG CTG GTG ACC TGG GTG GTC C - #CC CTC CTC TTC CTC TTC
 109
     Met Glu Pro Leu Val Thr Trp Val - # Val Pro Leu Leu Phe Leu Phe
#    15
- CTG CTG TCC AGG CAG GGC GCT GCC TGC AGA AC - #C AGT GAG TGC TGT TTT
 157
Leu Leu Ser Arg Gln Gly Ala Ala Cys Arg Th - #r Ser Glu Cys Cys Phe
#                 30
- CAG GAC CCG CCA TAT CCG GAT GCA GAC TCA GG - #C TCG GCC TCG GGC CCT
 205
Gln Asp Pro Pro Tyr Pro Asp Ala Asp Ser Gl - #y Ser Ala Ser Gly Pro
#             45
- AGG GAC CTG AGA TGC TAT CGG ATA TCC AGT GA - #T CGT TAC GAG TGC TCC
 253
Arg Asp Leu Arg Cys Tyr Arg Ile Ser Ser As - #p Arg Tyr Glu Cys Ser
#         60
- TGG CAG TAT GAG GGT CCC ACA GCT GGG GTC AG - #C CAC TTC CTG CGG TGT
 301
Trp Gln Tyr Glu Gly Pro Thr Ala Gly Val Se - #r His Phe Leu Arg Cys
#     75
- TGC CTT AGC TCC GGG CGC TGC TGC TAC TTC GC - #C GCC GGC TCA GCC ACC
 349
Cys Leu Ser Ser Gly Arg Cys Cys Tyr Phe Al - #a Ala Gly Ser Ala Thr
# 95
- AGG CTG CAG TTC TCC GAC CAG GCT GGG GTG TC - #T GTG CTG TAC ACT GTC
 397
Arg Leu Gln Phe Ser Asp Gln Ala Gly Val Se - #r Val Leu Tyr Thr Val
#               110
- ACA CTC TGG GTG GAA TCC TGG GCC AGG AAC CA - #G ACA GAG AAG TCT CCT
 445
Thr Leu Trp Val Glu Ser Trp Ala Arg Asn Gl - #n Thr Glu Lys Ser Pro
#           125
- GAG GTG ACC CTG CAG CTC TAC AAC TCA GTT AA - #A TAT GAG CCT CCT CTG
 493
Glu Val Thr Leu Gln Leu Tyr Asn Ser Val Ly - #s Tyr Glu Pro Pro Leu
#       140
- GGA GAC ATC AAG GTG TCC AAG TTG GCC GGG CA - #G CTG CGT ATG GAG TGG
 541
Gly Asp Ile Lys Val Ser Lys Leu Ala Gly Gl - #n Leu Arg Met Glu Trp
#   155
- GAG ACC CCG GAT AAC CAG GTT GGT GCT GAG GT - #G CAG TTC CGG CAC CGG
 589
Glu Thr Pro Asp Asn Gln Val Gly Ala Glu Va - #l Gln Phe Arg His Arg
160                 1 - #65                 1 - #70                 1 -
#75
- ACA CCC AGC AGC CCA TGG AAG TTG GGC GAC TG - #C GGA CCT CAG GAT GAT
 637
Thr Pro Ser Ser Pro Trp Lys Leu Gly Asp Cy - #s Gly Pro Gln Asp Asp
#               190
- GAT ACT GAG TCC TGC CTC TGC CCC CTG GAG AT - #G AAT GTG GCC CAG GAA
 685
Asp Thr Glu Ser Cys Leu Cys Pro Leu Glu Me - #t Asn Val Ala Gln Glu
#           205
- TTC CAG CTC CGA CGA CGG CAG CTG GGG AGC CA - #A GGA AGT TCC TGG AGC
 733
Phe Gln Leu Arg Arg Arg Gln Leu Gly Ser Gl - #n Gly Ser Ser Trp Ser
#       220
- AAG TGG AGC AGC CCC GTG TGC GTT CCC CCT GA - #A AAC CCC CCA CAG CCT
 781
Lys Trp Ser Ser Pro Val Cys Val Pro Pro Gl - #u Asn Pro Pro Gln Pro
#   235
- CAG GTG AGA TTC TCG GTG GAG CAG CTG GGC CA - #G GAT GGG AGG AGG CGG
 829
Gln Val Arg Phe Ser Val Glu Gln Leu Gly Gl - #n Asp Gly Arg Arg Arg
240                 2 - #45                 2 - #50                 2 -
#55
- CTG ACC CTG AAA GAG CAG CCA ACC CAG CTG GA - #G CTT CCA GAA GGC TGT
 877
Leu Thr Leu Lys Glu Gln Pro Thr Gln Leu Gl - #u Leu Pro Glu Gly Cys
#               270
- CAA GGG CTG GCG CCT GGC ACG GAG GTC ACT TA - #C CGA CTA CAG CTC CAC
 925
Gln Gly Leu Ala Pro Gly Thr Glu Val Thr Ty - #r Arg Leu Gln Leu His
#           285
- ATG CTG TCC TGC CCG TGT AAG GCC AAG GCC AC - #C AGG ACC CTG CAC CTG
 973
Met Leu Ser Cys Pro Cys Lys Ala Lys Ala Th - #r Arg Thr Leu His Leu
#       300
- GGG AAG ATG CCC TAT CTC TCG GGT GCT GCC TA - #C AAC GTG GCT GTC ATC
1021
Gly Lys Met Pro Tyr Leu Ser Gly Ala Ala Ty - #r Asn Val Ala Val Ile
#   315
- TCC TCG AAC CAA TTT GGT CCT GGC CTG AAC CA - #G ACG TGG CAC ATT CCT
1069
Ser Ser Asn Gln Phe Gly Pro Gly Leu Asn Gl - #n Thr Trp His Ile Pro
320                 3 - #25                 3 - #30                 3 -
#35
- GCC GAC ACC CAC ACA GAA CCA GTG GCT CTG AA - #T ATC AGC GTC GGA ACC
1117
Ala Asp Thr His Thr Glu Pro Val Ala Leu As - #n Ile Ser Val Gly Thr
#               350
- AAC GGG ACC ACC ATG TAT TGG CCA GCC CGG GC - #T CAG AGC ATG ACG TAT
1165
Asn Gly Thr Thr Met Tyr Trp Pro Ala Arg Al - #a Gln Ser Met Thr Tyr
#           365
- TGC ATT GAA TGG CAG CCT GTG GGC CAG GAC GG - #G GGC CTT GCC ACC TGC
1213
Cys Ile Glu Trp Gln Pro Val Gly Gln Asp Gl - #y Gly Leu Ala Thr Cys
#       380
- AGC CTG ACT GCG CCG CAA GAC CCG GAT CCG GC - #T GGA ATG GCA ACC TAC
1261
Ser Leu Thr Ala Pro Gln Asp Pro Asp Pro Al - #a Gly Met Ala Thr Tyr
#   395
- AGC TGG AGT CGA GAG TCT GGG GCA ATG GGG CA - #G GAA AAG TGT TAC TAC
1309
Ser Trp Ser Arg Glu Ser Gly Ala Met Gly Gl - #n Glu Lys Cys Tyr Tyr
400                 4 - #05                 4 - #10                 4 -
#15
- ATT ACC ATC TTT GCC TCT GCG CAC CCC GAG AA - #G CTC ACC TTG TGG TCT
1357
Ile Thr Ile Phe Ala Ser Ala His Pro Glu Ly - #s Leu Thr Leu Trp Ser
#               430
- ACG GTC CTG TCC ACC TAC CAC TTT GGG GGC AA - #T GCC TCA GCA GCT GGG
1405
Thr Val Leu Ser Thr Tyr His Phe Gly Gly As - #n Ala Ser Ala Ala Gly
#           445
- ACA CCG CAC CAC GTC TCG GTG AAG AAT CAT AG - #C TTG GAC TCT GTG TCT
1453
Thr Pro His His Val Ser Val Lys Asn His Se - #r Leu Asp Ser Val Ser
#       460
- GTG GAC TGG GCA CCA TCC CTG CTG AGC ACC TG - #T CCC GGC GTC CTA AAG
1501
Val Asp Trp Ala Pro Ser Leu Leu Ser Thr Cy - #s Pro Gly Val Leu Lys
#   475
- GAG TAT GTT GTC CGC TGC CGA GAT GAA GAC AG - #C AAA CAG GTG TCA GAG
1549
Glu Tyr Val Val Arg Cys Arg Asp Glu Asp Se - #r Lys Gln Val Ser Glu
480                 4 - #85                 4 - #90                 4 -
#95
- CAT CCC GTG CAG CCC ACA GAG ACC CAA GTT AC - #C CTC AGT GGC CTG CGG
1597
His Pro Val Gln Pro Thr Glu Thr Gln Val Th - #r Leu Ser Gly Leu Arg
#               510
- GCT GGT GTA GCC TAC ACG GTG CAG GTG CGA GC - #A GAC ACA GCG TGG CTG
1645
Ala Gly Val Ala Tyr Thr Val Gln Val Arg Al - #a Asp Thr Ala Trp Leu
#           525
- AGG GGT GTC TGG AGC CAG CCC CAG CGC TTC AG - #C ATC GAA GTG CAG GTT
1693
Arg Gly Val Trp Ser Gln Pro Gln Arg Phe Se - #r Ile Glu Val Gln Val
#       540
- TCT GAT TGG CTC ATC TTC TTC GCC TCC CTG GG - #G AGC TTC CTG AGC ATC
1741
Ser Asp Trp Leu Ile Phe Phe Ala Ser Leu Gl - #y Ser Phe Leu Ser Ile
#   555
- CTT CTC GTG GGC GTC CTT GGC TAC CTT GGC CT - #G AAC AGG GCC GCA CGG
1789
Leu Leu Val Gly Val Leu Gly Tyr Leu Gly Le - #u Asn Arg Ala Ala Arg
560                 5 - #65                 5 - #70                 5 -
#75
- CAC CTG TGC CCG CCG CTG CCC ACA CCC TGT GC - #C AGC TCC GCC ATT GAG
1837
His Leu Cys Pro Pro Leu Pro Thr Pro Cys Al - #a Ser Ser Ala Ile Glu
#               590
- TTC CCT GGA GGG AAG GAG ACT TGG CAG TGG AT - #C AAC CCA GTG GAC TTC
1885
Phe Pro Gly Gly Lys Glu Thr Trp Gln Trp Il - #e Asn Pro Val Asp Phe
#           605
- CAG GAA GAG GCA TCC CTG CAG GAG GCC CTG GT - #G GTA GAG ATG TCC TGG
1933
Gln Glu Glu Ala Ser Leu Gln Glu Ala Leu Va - #l Val Glu Met Ser Trp
#       620
- GAC AAA GGC GAG AGG ACT GAG CCT CTC GAG AA - #G ACA GAG CTA CCT GAG
1981
Asp Lys Gly Glu Arg Thr Glu Pro Leu Glu Ly - #s Thr Glu Leu Pro Glu
#   635
- GGT GCC CCT GAG CTG GCC CTG GAT ACA GAG TT - #G TCC TTG GAG GAT GGA
2029
Gly Ala Pro Glu Leu Ala Leu Asp Thr Glu Le - #u Ser Leu Glu Asp Gly
640                 6 - #45                 6 - #50                 6 -
#55
- GAC AGG TGC AAG GCC AAG ATG TGATCGTTGA GGCTCAGAG - #A GGGTGAGTGA
2080
Asp Arg Cys Lys Ala Lys Met
                660
#              2104TAGC CTTT
- (2) INFORMATION FOR SEQ ID NO:4:
-      (i) SEQUENCE CHARACTERISTICS:
#acids    (A) LENGTH: 662 amino
          (B) TYPE: amino acid
          (D) TOPOLOGY: linear
-     (ii) MOLECULE TYPE: protein
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 1..20
#/note= "N-terminal signal peptide
               (1..20 or - # 23 or 24)"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 541..570
#/note= "transmembrane region"N:
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 571..662
#/note= "cytoplasmic tail region"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 52..64
#/note= "sequence motif of cytokine
#superfamily Cys52..Cys62SW"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 222..226
#/note= "cytokine receptorATION:
#motif (W222SKWS)"erfamily
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 121..123
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 329..331
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 346..348
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 352..354
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 442..444
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 456..458
#/note= "N-linked glycosylation:
               site"
-     (ix) FEATURE:
          (A) NAME/KEY: Region
          (B) LOCATION: 24..540
#/note= "Extracellular region"N:
-     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
- Met Glu Pro Leu Val Thr Trp Val Val Pro Le - #u Leu Phe Leu Phe Leu
#                15
- Leu Ser Arg Gln Gly Ala Ala Cys Arg Thr Se - #r Glu Cys Cys Phe Gln
#            30
- Asp Pro Pro Tyr Pro Asp Ala Asp Ser Gly Se - #r Ala Ser Gly Pro Arg
#        45
- Asp Leu Arg Cys Tyr Arg Ile Ser Ser Asp Ar - #g Tyr Glu Cys Ser Trp
#    60
- Gln Tyr Glu Gly Pro Thr Ala Gly Val Ser Hi - #s Phe Leu Arg Cys Cys
#80
- Leu Ser Ser Gly Arg Cys Cys Tyr Phe Ala Al - #a Gly Ser Ala Thr Arg
#                95
- Leu Gln Phe Ser Asp Gln Ala Gly Val Ser Va - #l Leu Tyr Thr Val Thr
#           110
- Leu Trp Val Glu Ser Trp Ala Arg Asn Gln Th - #r Glu Lys Ser Pro Glu
#       125
- Val Thr Leu Gln Leu Tyr Asn Ser Val Lys Ty - #r Glu Pro Pro Leu Gly
#   140
- Asp Ile Lys Val Ser Lys Leu Ala Gly Gln Le - #u Arg Met Glu Trp Glu
145                 1 - #50                 1 - #55                 1 -
#60
- Thr Pro Asp Asn Gln Val Gly Ala Glu Val Gl - #n Phe Arg His Arg Thr
#               175
- Pro Ser Ser Pro Trp Lys Leu Gly Asp Cys Gl - #y Pro Gln Asp Asp Asp
#           190
- Thr Glu Ser Cys Leu Cys Pro Leu Glu Met As - #n Val Ala Gln Glu Phe
#       205
- Gln Leu Arg Arg Arg Gln Leu Gly Ser Gln Gl - #y Ser Ser Trp Ser Lys
#   220
- Trp Ser Ser Pro Val Cys Val Pro Pro Glu As - #n Pro Pro Gln Pro Gln
225                 2 - #30                 2 - #35                 2 -
#40
- Val Arg Phe Ser Val Glu Gln Leu Gly Gln As - #p Gly Arg Arg Arg Leu
#               255
- Thr Leu Lys Glu Gln Pro Thr Gln Leu Glu Le - #u Pro Glu Gly Cys Gln
#           270
- Gly Leu Ala Pro Gly Thr Glu Val Thr Tyr Ar - #g Leu Gln Leu His Met
#       285
- Leu Ser Cys Pro Cys Lys Ala Lys Ala Thr Ar - #g Thr Leu His Leu Gly
#   300
- Lys Met Pro Tyr Leu Ser Gly Ala Ala Tyr As - #n Val Ala Val Ile Ser
305                 3 - #10                 3 - #15                 3 -
#20
- Ser Asn Gln Phe Gly Pro Gly Leu Asn Gln Th - #r Trp His Ile Pro Ala
#               335
- Asp Thr His Thr Glu Pro Val Ala Leu Asn Il - #e Ser Val Gly Thr Asn
#           350
- Gly Thr Thr Met Tyr Trp Pro Ala Arg Ala Gl - #n Ser Met Thr Tyr Cys
#       365
- Ile Glu Trp Gln Pro Val Gly Gln Asp Gly Gl - #y Leu Ala Thr Cys Ser
#   380
- Leu Thr Ala Pro Gln Asp Pro Asp Pro Ala Gl - #y Met Ala Thr Tyr Ser
385                 3 - #90                 3 - #95                 4 -
#00
- Trp Ser Arg Glu Ser Gly Ala Met Gly Gln Gl - #u Lys Cys Tyr Tyr Ile
#               415
- Thr Ile Phe Ala Ser Ala His Pro Glu Lys Le - #u Thr Leu Trp Ser Thr
#           430
- Val Leu Ser Thr Tyr His Phe Gly Gly Asn Al - #a Ser Ala Ala Gly Thr
#       445
- Pro His His Val Ser Val Lys Asn His Ser Le - #u Asp Ser Val Ser Val
#   460
- Asp Trp Ala Pro Ser Leu Leu Ser Thr Cys Pr - #o Gly Val Leu Lys Glu
465                 4 - #70                 4 - #75                 4 -
#80
- Tyr Val Val Arg Cys Arg Asp Glu Asp Ser Ly - #s Gln Val Ser Glu His
#               495
- Pro Val Gln Pro Thr Glu Thr Gln Val Thr Le - #u Ser Gly Leu Arg Ala
#           510
- Gly Val Ala Tyr Thr Val Gln Val Arg Ala As - #p Thr Ala Trp Leu Arg
#       525
- Gly Val Trp Ser Gln Pro Gln Arg Phe Ser Il - #e Glu Val Gln Val Ser
#   540
- Asp Trp Leu Ile Phe Phe Ala Ser Leu Gly Se - #r Phe Leu Ser Ile Leu
545                 5 - #50                 5 - #55                 5 -
#60
- Leu Val Gly Val Leu Gly Tyr Leu Gly Leu As - #n Arg Ala Ala Arg His
#               575
- Leu Cys Pro Pro Leu Pro Thr Pro Cys Ala Se - #r Ser Ala Ile Glu Phe
#           590
- Pro Gly Gly Lys Glu Thr Trp Gln Trp Ile As - #n Pro Val Asp Phe Gln
#       605
- Glu Glu Ala Ser Leu Gln Glu Ala Leu Val Va - #l Glu Met Ser Trp Asp
#   620
- Lys Gly Glu Arg Thr Glu Pro Leu Glu Lys Th - #r Glu Leu Pro Glu Gly
625                 6 - #30                 6 - #35                 6 -
#40
- Ala Pro Glu Leu Ala Leu Asp Thr Glu Leu Se - #r Leu Glu Asp Gly Asp
#               655
- Arg Cys Lys Ala Lys Met
            660
__________________________________________________________________________

Claims (2)

We claim:

1. A human interleukin-12 (IL-12) beta2 receptor protein which has the amino acid sequence SEQ ID NO:2, or a protein which has an amino acid sequence which is encoded by a nucleic acid sequence which hybridizes under stringent conditions to the nucleic acid sequence which encodes SEQ ID NO:2, which protein

(a) has low binding affinity for human IL-12, and

(b) when complexed with a human IL-12 beta1 receptor protein forms a complex having high binding affinity to human IL-12, the protein being free from other human proteins.

2. The human IL-12 beta2 receptor protein of claim 1, having SEQ ID NO:2.